Integrated Wellness · Research education
Compare the science.
Put two to four molecules side by side. Similar goals do not mean similar mechanisms, evidence or risks.
Choose your molecules
4 of 4 selected · Choose at least 2
Explore a comparison:
On smaller screens, scroll the table sideways to see each molecule.
| Research dimension | CJC-1295 Human research | Ipamorelin Human research | PEG-MGF Preclinical | IGF-1 LR3 Preclinical |
|---|---|---|---|---|
| Biological classification | Long-acting GHRH analog | Synthetic pentapeptide secretagogue | Pegylated MGF-related research construct | Modified long-acting IGF-1 analog |
| Mechanism & pathway | A synthetic growth hormone-releasing hormone analog. The long-acting DAC form binds albumin to prolong exposure and stimulates the GHRH receptor upstream of GH/IGF-1. | Stimulates GH release through ghrelin-receptor/secretagogue signaling, rather than the GHRH receptor. Selectivity reported in preclinical models does not guarantee absence of adverse effects in people. | A pegylated research construct related to the E-domain of an IGF-1 splice variant. It is not interchangeable with full-length MGF or non-pegylated MGF-E. | Activates IGF-1 receptor signaling with altered interactions with IGF-binding proteins compared with native IGF-1. Experimental effects on growth and metabolism are not proof of safe human use. |
| Investigated applications | GH and IGF-1 responses and pharmacokinetics in controlled research. | GH signaling and gastrointestinal motility research. | Muscle progenitor-cell and growth-factor biology. | Growth-factor signaling in cell culture and animal models. |
| Evidence quality | Human research | Human research | Preclinical | Preclinical |
| What remains uncertain | The cited trial studies the long-acting DAC form and hormone responses, not proof of improved recovery or anti-aging benefit. Modified GRF (1–29) without DAC is not interchangeable. | The foundational linked study is preclinical. A separate human postoperative-ileus trial does not establish anti-aging or recovery benefit. | The cited papers concern MGF-E peptide in cells and analytical characterization of full-length MGF—not clinical testing of PEG-MGF. | Animal organ-growth research and analytical identification of a product are not clinical efficacy trials. LR3 is not mecasermin, an approved IGF-1 medication. |
| Safety considerations | Potential glucose intolerance, fluid retention and endocrine effects; FDA reports increased heart rate and systemic vasodilatory reactions. | FDA notes serious adverse events including deaths in an intravenous motility study and insufficient safety information for other injectable routes; this does not by itself establish causality. | Human safety of PEG-MGF is not established. FDA identifies potential immunogenicity and no identified human exposure data for nominated drug products. | IGF signaling can affect glucose and growth pathways; hypoglycemia and unintended tissue growth are concerns. Human safety for this analog is not established. |
| Regulatory classification | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. | Not FDA-approvedNo FDA-approved finished drug for this molecule is identified in this edition. Investigational use, published research or compounding does not establish FDA approval. |
Comparing molecules is not a recommendation to combine them. Clinical evidence for one product or indication cannot establish another’s safety or effectiveness. Open each profile for study types, source links and important evidence limitations.